Optimization of an Online Stepwise Therapeutic Device Based on a Cognitive-behavioral Approach for Cancer Patients With Insomnia
NCT ID: NCT05977062
Last Updated: 2023-08-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
322 participants
INTERVENTIONAL
2022-02-25
2024-10-13
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Video-Based Cognitive Behavioral Therapy for Insomnia in Adults Cancer Patients and Survivors
NCT03981666
Sleep Treatment Education Program for Cancer Survivors: STEP-Together
NCT06736548
Sleep Treatment Education Program-1 (STEP-1)
NCT05519982
Sleep Well At Night
NCT07068971
Efficacy of Synchronous, Virtual Cognitive Behavioral Therapy for Insomnia Across Phases of Cancer Survivorship
NCT06807086
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
SUPPORTIVE_CARE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Coaching arm
Self screening
Score ISI (Index de Sévérité de l'Insomnie)
Phone call
Phone call at the beginning of the program and at the middle and at the end.
Online questionnaires
To be completed at week 1, 6, 12 and 24.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Self screening
Score ISI (Index de Sévérité de l'Insomnie)
Phone call
Phone call at the beginning of the program and at the middle and at the end.
Online questionnaires
To be completed at week 1, 6, 12 and 24.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* With a diagnosis of localized or metastatic cancer,
* During or after their treatment,
* In one of the following three cancer centres: Gustave Roussy (Villejuif), Montpellier Cancer Institute (Montpellier), and Léon Bérard Center (Lyon)
* With a significative score on the self-screening Insomnia Severity Index score (ISI ≥ 8)
* Able to readily read and understand French,
* Able to use informatic tools confidently and with Internet access,
* Who have signed the online consent form,
* Affiliated to a social security system or beneficiary of the same.
Exclusion Criteria
* Simultaneous participation in another study evaluating a treatment of insomnia,
* Patient under guardianship or deprived of his liberty by a judicial or administrative decision or incapable of giving its consent.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Gustave Roussy, Cancer Campus, Grand Paris
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Diane BOINON, MD
Role: STUDY_CHAIR
Gustave Roussy, Cancer Campus, Grand Paris
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre Léon Bérard
Lyon, , France
Institut de Cancérologie de Montpellier
Montpellier, , France
Gustave Roussy
Villejuif, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2021/3317
Identifier Type: OTHER
Identifier Source: secondary_id
2021-A01891-40
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.